TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24607797

Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol vaginally 6 hours before HSG
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac potassium orally 45 to 60 minutes before HSG
Number of subjects: 168

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 168
Study: 23189083

Group type: EXPERIMENTAL
Intervention: Exercise intervention (90 min/day, 2 days/week, 80 times for 12 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 100
Study: 20394870

Group type: EXPERIMENTAL
Intervention: Omega-3 ethyl esters (1 g/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17385961

Group type: EXPERIMENTAL
Intervention: Peer-enhanced motivational intervention (PMI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Individual motivational intervention (IMI)
Number of subjects: 36
Study: 15565439

Group type: EXPERIMENTAL
Intervention: Potassium citrate (60 mEq/day) for 1 month
Number of subjects: 30
Study: 11865829

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 10539755

Group type: EXPERIMENTAL
Intervention: High-sn-2 formula
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard formula (control)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 203
Study: 7774036

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 63
Study: 1692612

Group type: EXPERIMENTAL
Intervention: Bovine surfactant therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 389827

Group type: EXPERIMENTAL
Intervention: Bacampicillin (800 mg t.i.d. for 10 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pivampicillin (700 mg t.i.d. for 10 days)
Number of subjects: 72
Study: 31997387

Group type: EXPERIMENTAL
Intervention: WOWW intervention
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 413
Study: 28945060

Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF) 1000 mg daily for 2 weeks before and for at least 2 months after sclerotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sclerotherapy alone (control)
Number of subjects: 60
Study: 27612500

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 12
Study: 25739243

Group type: EXPERIMENTAL
Intervention: Skeletal traction
Number of subjects: 68

Group type: COMPARATOR
Intervention: Skin traction
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 24305085

Group type: EXPERIMENTAL
Intervention: Treatment with immediate feedback for each session
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment without feedback
Number of subjects: 180
Study: 20429841

Group type: EXPERIMENTAL
Intervention: 4‐Oxo‐4,5,6,7‐tetrahydro‐1H‐indole‐3‐carboxylic acid (1)
Number of subjects: 0
Study: 18199015

Group type: EXPERIMENTAL
Intervention: Guided imagery therapy (listening to a 25-minute guided imagery CD twice a day for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (resting for 25 minutes twice daily for 8 weeks)
Number of subjects: 30
Study: 15836942

Group type: EXPERIMENTAL
Intervention: Diabetic group (n=16)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 16
Study: 14565594

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) plus calcium (1000 mg/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 77
Study: 10440419

Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clopidogrel 100 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (multiple doses for 14 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (long-term study for 12 weeks)
Number of subjects: 65
Study: 8985840

Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rutter A Questionnaire
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Parental concerns
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Absenteeism
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Distraction during school work
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Social problems
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bullying
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Holiday difficulties
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Behaviour problems
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Disruption of work
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Taking holidays
Number of subjects: 16
Study: 1815302

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pyridostigmine plus GHRH (1 micrograms/kg b.w. i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pyridostigmine plus GHRH
Number of subjects: 10
Study: 6368445

Group type: EXPERIMENTAL
Intervention: De-Nol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antacid mixture
Number of subjects: 40
Study: 30221619

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29582631

Group type: EXPERIMENTAL
Intervention: Educational intervention based on Protection Motivation Theory (PMT) over six sessions
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 143
Study: 27010625

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab administered monthly
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab administered as needed (PRN)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab administered monthly
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab administered as needed (PRN)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: PRN treatment
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Early responders
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Early responders vs delayed responders at baseline
Number of subjects: 1097
Study: 25439809

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (67 μg/kg/day) for 1 year followed by 2 years of randomized GH treatment (67 μg/kg/day, 35 μg/kg/day, or IGF‐I titrated)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 18
Study: 22824537

Group type: EXPERIMENTAL
Intervention: Home-based educational intervention (two sessions at the patient's home, one with the patient and one with their social network)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 160
Study: 21211259

Group type: EXPERIMENTAL
Intervention: Single B-Twin expandable spinal spacer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Double B-Twin expandable spinal spacer
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison between Single and Double B-Twin expandable spinal spacer
Number of subjects: 45
Study: 18284652

Group type: EXPERIMENTAL
Intervention: Lactulose (10 g b.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG 4000)
Number of subjects: 10
Study: 16321128

Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (standardised educational session about exercise rehabilitation)
Number of subjects: 133
Study: 14527648

Group type: EXPERIMENTAL
Intervention: 4-cm HHC-based VAS
Number of subjects: 96

Group type: COMPARATOR
Intervention: 10-cm paper-based VAS
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HHC-based items
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HHC-based VAS
Number of subjects: 96
Study: 11230031

Group type: EXPERIMENTAL
Intervention: Focal psychoanalytic psychotherapy for 1 year
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cognitive-analytic therapy (CAT) for 7 months
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Family therapy for 1 year
Number of subjects: 84

Group type: COMPARATOR
Intervention: Low contact, 'routine' treatment for 1 year
Number of subjects: 84
Study: 9407746

Group type: EXPERIMENTAL
Intervention: Running at a grade of -1.8%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Running at a grade of -3.6%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Running at a grade of -5.4%
Number of subjects: 13

Group type: COMPARATOR
Intervention: Level running (0% grade)
Number of subjects: 13
Study: 7684457

Group type: EXPERIMENTAL
Intervention: 7.5% NaCl (HS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.5% NaCl in 6% dextran 70 (HSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 0
Study: 3427224

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus Adriamycin followed by high-dose methotrexate plus cisplatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate plus cisplatin followed by Cyclophosphamide plus Adriamycin
Number of subjects: 20
Study: 31670794

Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg no load
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 31863697

Group type: EXPERIMENTAL
Intervention: Three option multiple-choice questions (MCQs)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Four option multiple-choice questions (MCQs)
Number of subjects: 3
Study: 29160391

Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Negative control (saline solution)
Number of subjects: 12
Study: 25466604

Group type: EXPERIMENTAL
Intervention: Small media print intervention (SMPI)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Tailored interactive multimedia intervention (TIMI)
Number of subjects: 665

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 665
Study: 23358760

Group type: EXPERIMENTAL
Intervention: P2 Group (more intensive educational nutritional intervention)
Number of subjects: 52

Group type: COMPARATOR
Intervention: P1 Group (less intensive educational nutritional intervention)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: P2 Group
Number of subjects: 52
Study: 21597989

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (all doses)
Number of subjects: 0
Study: 18334815

Group type: EXPERIMENTAL
Intervention: Beta-glucan-enriched ready meal (4 g of oat beta-glucans)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control soup (without oat beta-glucans)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Beta-glucan-enriched ready meal
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control soup
Number of subjects: 43
Study: 17136462

Group type: EXPERIMENTAL
Intervention: Life Skills Training prevention program
Number of subjects: 4858

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4858
Study: 12966366

Group type: EXPERIMENTAL
Intervention: 100 mg aceclofenac
Number of subjects: 0

Group type: COMPARATOR
Intervention: 75 mg diclofenac
Number of subjects: 0
Study: 11089711

Group type: EXPERIMENTAL
Intervention: Ischemic Heart Disease Shared Decision‐Making Program (IHD SDP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (usual practice)
Number of subjects: 240
Study: 9322828

Group type: EXPERIMENTAL
Intervention: Valsartan 80/160 mg
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Valsartan 80/80 mg twice daily
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Lisinopril 10/20 mg
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Valsartan and Lisinopril
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 734
Study: 7690462

Group type: EXPERIMENTAL
Intervention: L-697,661 (25 mg twice a day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: L-697,661 (100 mg three times a day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: L-697,661 (500 mg twice a day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Zidovudine (100 mg five times a day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: L-697,661 (all doses)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: L-697,661 (higher doses)
Number of subjects: 135
Study: 30507281

Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 58
Study: 29958570

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg via two infusions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral iron polymaltose complex (100 mg orally twice a day for 8 weeks)
Number of subjects: 56
Study: 26763349

Group type: EXPERIMENTAL
Intervention: Lenalidomide starting dose of 5 mg/d
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lenalidomide starting dose of 10 mg/d
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lenalidomide starting dose of 15 mg/d
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Escalated treatment (to 15 or 20 mg/d)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lenalidomide (any starting dose)
Number of subjects: 103
Study: 24531938

Group type: EXPERIMENTAL
Intervention: Periarticular infiltration analgesia (PIA) with 60 ml 0.5 % ropivacaine and 0.3 mg epinephrine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sciatic nerve block (SNB) with 20 ml 0.375 % ropivacaine and periarticular infiltration with 20 ml normal saline and 0.3 mg epinephrine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Periarticular infiltration (PIA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sciatic nerve block (SNB)
Number of subjects: 49
Study: 22218122

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (500 mg, 2 tablets per day for 5 days before transplantation)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 21535171

Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B (NBUVB) + isotretinoin (0.5 mg/kg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Narrow band ultraviolet B (NBUVB) + placebo
Number of subjects: 39
Study: 17047667

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 0
Study: 16236845

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 552

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 552
Study: 12198699

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nadolol plus isosorbide mononitrate (N+I)
Number of subjects: 121
Study: 10607989

Group type: EXPERIMENTAL
Intervention: Crude dust extract (CDE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8657436

Group type: EXPERIMENTAL
Intervention: beta‐methasone intrathecally prior to wound closure
Number of subjects: 26

Group type: COMPARATOR
Intervention: normal saline (placebo)
Number of subjects: 26
Study: 2089089

Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: brofaromine
Number of subjects: 53

Group type: COMPARATOR
Intervention: maprotiline
Number of subjects: 53
Study: 24645

Group type: EXPERIMENTAL
Intervention: Halazepam (40 mg starting dose, adjusted every 2 hours, total daily dose not exceeding 600 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31821349

Group type: EXPERIMENTAL
Intervention: Kinesiology taping (KT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Standard 'rigid' taping (ST)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham taping (ShT)
Number of subjects: 54
Study: 28456947

Group type: EXPERIMENTAL
Intervention: Routine discussion of sexual orientation and HPV vaccination
Number of subjects: 220

Group type: COMPARATOR
Intervention: Not discussing sexual orientation and HPV vaccination
Number of subjects: 220
Study: 26951777

Group type: EXPERIMENTAL
Intervention: Induction of labour at 41 GW (early induction)
Number of subjects: 10038

Group type: COMPARATOR
Intervention: Expectant management and induction at 42 GW (late induction)
Number of subjects: 10038
Study: 24528686

Group type: EXPERIMENTAL
Intervention: Armolipid Plus (nutraceutical combination containing red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pravastatin 10 mg/d
Number of subjects: 30
Study: 22492764

Group type: EXPERIMENTAL
Intervention: RC with Lactobacillus reuteri DSM17938 (reuteri)
Number of subjects: 494

Group type: COMPARATOR
Intervention: RC (regular calcium content)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: RC with Lactobacillus casei CRL431 (casei)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Low-lactose milk with low calcium content (LC)
Number of subjects: 494
Study: 20932058

Group type: EXPERIMENTAL
Intervention: Exercise session with 10 seconds rest interval
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise session with 1 minute rest interval
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pre-exercise samples
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-exercise samples
Number of subjects: 12
Study: 17621463

Group type: EXPERIMENTAL
Intervention: Tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV)
Number of subjects: 86
Study: 15304466

Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for the duration of PCI) with provisional Gp IIb/IIIa inhibition
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Heparin (65 U/kg bolus) with planned Gp IIb/IIIa inhibition
Number of subjects: 6010
Study: 19785243

Group type: EXPERIMENTAL
Intervention: Submaximal voluntary contraction (SVC) exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Near-maximal voluntary contraction (NMVC) exercise
Number of subjects: 32
Study: 9638490

Group type: EXPERIMENTAL
Intervention: Combined tele- and brachytherapy (44 +/- 3 Gy external beam radiation followed by 20 +/- 4 Gy interstitial brachytherapy with iridium-192)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control subjects (not specified how many)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined tele- and brachytherapy
Number of subjects: 8
Study: 8131429

Group type: EXPERIMENTAL
Intervention: Videofluoroscopic evidence of aspiration (aspirating any amount of barium)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Videofluoroscopic evidence of aspiration (aspirating thickened liquids or more solid consistencies)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (dysphagic controls without aspiration)
Number of subjects: 59
Study: 2506594

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 236810

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31370099

Group type: EXPERIMENTAL
Intervention: Neonatal mortality
Number of subjects: 381567

Group type: EXPERIMENTAL
Intervention: Apgar score <7 at 5 minutes
Number of subjects: 381567

Group type: EXPERIMENTAL
Intervention: Emergency cesarean section
Number of subjects: 381567
Study: 30853361

Group type: EXPERIMENTAL
Intervention: Dose-dense taxane chemotherapy (ddTC)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional taxane and carboplatin chemotherapy (TC)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for MT subtype
Number of subjects: 201

Group type: COMPARATOR
Intervention: Overall survival (OS) for other subtypes
Number of subjects: 201
Study: 28924270

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system
Number of subjects: 76

Group type: COMPARATOR
Intervention: Norethisterone
Number of subjects: 76
Study: 25774838

Group type: EXPERIMENTAL
Intervention: Biofeedback training with real-time BP feedback signals
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group trained with pseudofeedback signals
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups (biofeedback and control)
Number of subjects: 59
Study: 25059982

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 22
Study: 22584132

Group type: EXPERIMENTAL
Intervention: Insulin detemir (n = 162)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Continuation without insulin detemir (n = 157)
Number of subjects: 988
Study: 19084016

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 mug) weekly for 48 weeks and ribavirin (1000-1200 mg) daily for HCV genotype 1
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily for HCV genotypes 2 or 3
Number of subjects: 321

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 321
Study: 16997472

Group type: EXPERIMENTAL
Intervention: Higher levels of Pain Readiness to Change (high ACT scores)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Higher levels of Pain Readiness to Change (high ACT scores) and increased positive affect
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pain Readiness to Change
Number of subjects: 40